The Impact Of The Revolutionary I-SPY 2 TRIAL On Early Stage, High-Risk Breast Cancer Treatment: The Future Of Clinical Trials
SAN FRANCISCO, Sept. 7, 2018 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announce their upcoming press conference on September 12, 2018 at the National Press Club in Washington, DC. A press release on September 12 will precede the press event.
WHAT: For almost a century, the
randomized clinical trial
(RCT) has been the principal
tool driving the development
of new and better medical
treatments. However,
realizing the promise of
precision medicine requires
a profound shift in our
approach to clinical
research with improved
tools, new conventions for
assessment, and a modernized
system for approvals that
ensures and enhances patient
safety and minimizes
toxicity. This new approach
will move us from the "one
drug, one trial" approach
commonly used today, to a
model that promotes
continuous learning and
improvement in outcomes.
The essential tool of this
new approach is the
adaptive, platform trial - a
continuous, multi-treatment
clinical trial model that
refines the biological
targeting of treatment as it
learns. Although there are
now a number of such trials
underway, the I-SPY 2 TRIAL
is one of the first, and now
the longest running platform
trial. It is also the most
successful and the benchmark
example of the power and
possibilities of this new
approach.
In this forum, the
physicians, scientists, and
regulators who are leading
the charge in this
revolution in clinical care
and research, will describe
the vision, current
progress, and implications
in the treatment of disease.
Researchers and patients
from the groundbreaking I-
SPY 2 TRIAL will highlight
their progress in improving
outcomes for early, high-
risk breast cancer and their
plans to further positively
disrupt the clinical trial
space.
Following the forum, members
of the press are invited to
a seminar designed for
science writers to provide
additional detail and answer
questions.
WHO: Key speakers include: Dr.
Laura Esserman, Founder and
Co-Principal Investigator
of the I-SPY Trials; Dr.
Janet Woodcock, Director of
the Center for Drug
Evaluation and Research,
FDA; Dr. Anna D Barker, Co-
director, Complex Adaptive
Systems-Biomedicine, and
Director of Transformative
Healthcare Networks at
Arizona State University;
and Dr. Donald A Berry, I-
SPY 2 Co-Principal
Investigator and lead
statistician of Berry
Consultants.
WHEN: Wednesday, September 12, 2018
Press Briefing: 2:00-3:40 pm
ET (light lunch at 12:45 pm
ET)
Science writer seminar:
3:45-5:00 pm ET
WHERE: The National Press Club | 529
4th St, NW, 13th Floor |
Washington, DC
RSVP: Kristen Zeitzer
Director of Marketing and
Communications
Quantum Leap Healthcare
Collaborative
(415) 215-6893;
k.zeitzer@quantumleaphealth.org
About Quantum Leap Healthcare Collaborative
Quantum Leap Healthcare Collaborative (QLHC) is a 501C(3) charitable organization established in 2005 as a collaboration between medical researchers at University of California, San Francisco and Silicon Valley entrepreneurs. Our mission is to integrate high-impact research with clinical processes and systems technology, resulting in improved data management and information systems, greater access to clinical trial matching and sponsorship, and greater benefit to providers, patients and researchers. Our goal is to improve and save lives. Quantum Leap provides operational, financial, and regulatory oversight to I-SPY. For more information, visit https://www.quantumleaphealth.org/.
View original content with multimedia:http://www.prnewswire.com/news-releases/the-impact-of-the-revolutionary-i-spy-2-trial-on-early-stage-high-risk-breast-cancer-treatment-the-future-of-clinical-trials-300708648.html
SOURCE Quantum Leap Healthcare Collaborative
